Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1995-09-12
1998-03-10
Tsang, Cecilia J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 17, 514 18, 530317, 530322, 530329, 530330, A61K 3800
Patent
active
057261563
ABSTRACT:
The present invention relates to novel peptides that are potent cytokine regulatory agents. In addition, the present invention relates to pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a cytokine regulatory agent. Administration of such a cytokine regulatory agent to a subject can enhance or restrain cytokine activity. Thus, the present invention provides a method of regulating cytokine activity in a subject having a condition characterized by aberrant or altered cytokine activity. The invention also provides methods of treating such conditions, including, for example, disuse deconditioning, diseases mediated by nitric oxide and cytokines, adverse drug reactions, obesity, septic shock, and adverse side effects due to cancer chemotherapy or occurring as in response to organ transplantation.
REFERENCES:
patent: 4457864 (1984-07-01), Hruby et al.
patent: 4485039 (1984-11-01), Hruby et al.
patent: 4649191 (1987-03-01), Hruby
patent: 4866038 (1989-09-01), Hruby et al.
patent: 4918055 (1990-04-01), Hruby et al.
patent: 5028592 (1991-07-01), Lipton
patent: 5049547 (1991-09-01), Hruby et al.
patent: 5157023 (1992-10-01), Lipton
patent: 5408038 (1995-04-01), Smith et al.
patent: 5420109 (1995-05-01), Suto et al.
patent: 5462927 (1995-10-01), Moreau
Dayhoff, Atlas of Protein Sequence and Structure, vol. 5, 1972, p. 96.
Abou-Mohamed et al., "HP-228, a novel synthetic peptide, inhibits the induction of nitric oxide synthase in vivo but no in vitro." J. Pharmacol. Exp. Ther., 275(2):584-591 (Jul. 21, 1995).
Dinarello et al., "The role of interleukin-1 in disease." New England J. Med., 328:106-113 (1993).
Richards and Lipton, "Effect of .alpha.-MSH 11-13 (Lysine-Proline-Valine) on Fever in the Rabbit." Peptides, 5:815-817 (1984).
Deeter et al., "Antipyretic properties of centrally administered .alpha.-MSH fragments in the rabbit." Peptides 9:1285-1288 (1989).
Sugg et al., "D-Isomeric replacements within the 6-9 core sequence of a the solution conformation of .alpha.-Melanotropin." Biopolymers, 25:2029-2042 (1986).
Norlund, James J., ".alpha.-Melanocyte-stimulating hormone a ubiquitous cytokine with pigmenting effects." J. Amer. Med. Assoc., 226:2753-2754 (1991).
Levine et al., "Induction of skin tanning by subcutaneous administration of a potent synthetic melanotropin." J. Amer. Med. Assoc., 266:2730-2736 (1991).
Al-Obeidi et al., "Design of a new class of superpotent cyclic .alpha.-melanotrophins based on quenched dynamic simulations." J. Am. Chem. Soc., 111:3413-3416 (1989).
Poole et al., "Peripheral analgesic activities of peptides related to .alpha.-melanocyte stimulating hormone and interleukin-1.beta..sup.193-195." Br. J. Pharmacol. 106:489-492 (1992).
Follenfant et al., "Inhibition by neuropeptides of interleukin-1 .beta.-induced prostaglandin-independent hyperalgesia." Br. J. Pharmacol., 98:41-43 (1989).
Rivier et al., "In the mouse, the activation of the hypothalamic-pituitary-adrenal axis by a lipopolysaccharide (Endotoxin) is mediated through interleukin-1." Endocrinology, 125(60):2800-2805 (1989).
Vinegar et al., "Biphasic development of carrageenin edema in rats." J. of Pharmacol. and Exper. Therapeutics, 166(1):96-103 (1969).
Vinegar et al., "Pathway to carrageenan-induced inflammation in the hind limb of the rat." Federation Proc., 46:118-126 (1987).
Hiltz and Lipton, "Alpha-MSH peptides inhibit acute inflammation and contact sensitivity." Peptides, 11(5):979-982 (1990).
Ray et al., "Cytokines and their receptors: Molecular mechanism of interleukin-6 gene repression by glucocorticoids." J. Am. Soc. Nephrol., 2:S214-S221 (1992).
Karkar et al., "Passive immunization against tumor necrosis factor-alpha (TNF-.alpha.) and IL-1.beta. protects from LPS enhancing glomerular injury in nephrotoxic nephritis in rats." Clin. Exp. Immunol., 90:312-318 (1992).
Ulich et al., "Indotoxin-induced cytokine gene expression in vivo." Am. J. of Pathol., 141(1):61-68 (1992).
Jansen et al., "Induction of nitric oxide synthase in rat immune complex glomerulonephritis." Kidney Int'l., 45:1215-1219 (1994).
Mackensen et al., "Treatment of cancer patients with endotoxin induces release of endogenous cytokines." Pathobiol., 59:264-267 (1991).
Mackensen et al., "Modulating activity of interferon-.gamma. on endotoxin-induced cytokine production in cancer patients." Blood, 78(12):3254-3258 (1991).
Rabinowitz et al., "Characterization on endogenous cytokine concentrations after high-dose chemotherapy with antologous bone marrow support." Blood, 81(9):2452-2459 (1993).
Mosmann Tim R., "Interleukin-10." The Cytokine Handbook, 2nd Ed., Ch. 12 (1994).
Moore et al., "Interleukin-10." Annu. Rev. Immunol., 11:165-190 (1993).
Chernoff et al., "A randomized, controlled trial of IL-10 in humans: Inhibition of inflammatory cytokine production and immune responses." J. of Immunol., 154:5492-5499 (1995).
Rennick et al., "Interleukin 10: An overview." Progress in Growth Factor Research, 4:207-227 (1992).
Spits and Malefyt, "Funcational characterization of human IL-10." Int. Arch. Allery Immunol., 99:8-15 (1992).
Cassatella et al., "Interleukin 10 (IL-10) upregulates IL-1 receptor antagonist production from lipoplysaccharide-stimulated human polymorphonuclear leukocytes by delaying mRNA degradation." J. Exp. Med., 179:1695-1699 (1994).
Marchant et al., "Interleukin-10 controls interferon-.gamma. and tumor necrosis factor production during experimental endotoxemia." Eur. J. Immunol., 24:1167-1171 (1994).
Katsikis et al., "Immunoregulatory role of interleukin 10 in rheumatoid arthritis." J. Exp. Med., 179:1517-1527 (1994).
Gerard et al., "Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia." J. Exp. Med., 177:547-550 (1993).
Ward et al., "Aerobic training and diabetic nephropathy in the obese zucker rat." Annals of Clinical and Laboratory Science, 24(3):266-277 (1994).
T.B. NG, "Studies on hormonal regulation of lipolysis and lipogenesis in fat cells of various mammalian species." Comparative Biochem. and Phys. B: Comparative Biochem., 97(3):441-446 (1990).
Hotamislig and Spiegelman, "Tumor necrosis factor .alpha.: A key component of the obesity-diabetes link." Diabetes, 43:1271-1278 (1994).
Hotamislig et al., "Increased adipose tissue expression of tumor necrosis factor-.alpha. in human obesity and insulin resistance." J. Clin. Invest., 95:2409-2415 (1995).
Hotamislig et al., "Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes: Central role of tumor necrosis factor-.alpha.." J. Clin. Invest., 94:1543-1549 (1994).
Weinsier et al., "Metabolic predictors of obesity: Contribution of resting energy expenditure, themic effect of food, and fuel utilization to four-year weight gain of post-obese and never-obese women." J. Clin. Invest., 95:980-985 (1995).
Creekmore et al., "Strategies for clinical monitoring of therapeutic trials." Manual of Clin. Lab. Immunol., 915-922 (1992).
Thavasu et al., "Measuring cytokine levels in blood: Importance of anticoagulants, processing, and storage conditions." J.of Immunol. Methods, 153:115-124 (1992).
Payne et al., "Hypothalamic releasing hormones mediating the effects of interleukin-1 on sleep." J. of Cell. Biochem., 53:309-313 (1993).
Tilg et al., "Interleukin-6 (IL-6) as an anti-inflammatory cytokine: Induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55." Blood, 83(1):113-118 (1994).
Wong et al., "Interleukin (IL) 4 differentially regulates monocyte IL-1 family gene expression and synthesis in vitro and in vivo." J. of Exp. Med., 177:775-781 (1993).
Gorgen et al., "Granulocyte colony-stimulating factor treatment protects rodents against lipopolysaccaride-induced toxicity via suppression of systemic tumor necrosis factor-.alpha.." J. of Immunol., 149:918-924 (1992).
Andalibi Ali
Basu Amaresh
Fagan Patrick
Girten Beverly E.
Houghten Richard A.
Delacroix-Muirheid C.
Trega Biosciences, Inc.
Tsang Cecilia J.
LandOfFree
Cytokine regulatory agents and methods of use in pathologies and does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cytokine regulatory agents and methods of use in pathologies and, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cytokine regulatory agents and methods of use in pathologies and will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-139398